TheraRadar
← Back
Data updated: Jun 28, 2026

JIANGSU HANSOH PHARM

Generics
OncologyMetabolicInfectious Disease Execution: Needs Improvement

JIANGSU HANSOH PHARM is a generic drug manufacturer focused on Oncology, Metabolic, Infectious Disease.

2012
Since
11
Drugs
-
Trials
1
New Drugs (2yr)

JIANGSU HANSOH PHARM at a Glance

  • Growing R&D activity with 33 trials in last 2 years
  • Fast trial execution (15 months median completion)

JIANGSU HANSOH PHARM's Key Drugs

JIANGSU HANSOH PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

JIANGSU HANSOH PHARM's Recent FDA Approvals

JIANGSU HANSOH PHARM secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

BORTEZOMIB NDA
2024-08-26
bortezomib
1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: • treatment of adult patients with multiple myeloma ( 1.1 ) • treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

JIANGSU HANSOH PHARM's Therapeutic Areas

JIANGSU HANSOH PHARM's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 58%
4 drugs Phase 3: 3 Phase 2: 1 Phase 1: 18
Metabolic 21%
0 drugs Phase 3: 3 Phase 2: 3 Phase 1: 2
Infectious Disease 13%
1 drugs Phase 3: 1 Phase 2: 1 Phase 1: 1
Immunology 7%
0 drugs Phase 3: 1 Phase 1: 3
Gastroenterology 1%
0 drugs Phase 1: 1

JIANGSU HANSOH PHARM Pipeline Snapshot

JIANGSU HANSOH PHARM has 38 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 5 Phase 2 and 25 Phase 1.

8
Phase 3
5
Phase 2
25
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 4/10 completed
  • • Speed: 15 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges